MetaStat, Inc. (OTCQB:MTST), a molecular diagnostic company focused on
understanding and treating systemic metastasis, announced that Oscar L.
Bronsther, M.D., Chief Executive Officer, is scheduled to speak at the 13th
Annual BIO Investor Forum on October 8, 2014 at 2:00 pm PDT in San
Francisco. Dr. Bronsther will provide an update on the Company’s
business activities.
MetaStat’s presentation will be held in the Presidio Room of the Palace
Hotel in San Francisco. A live, listen-only audio webcast will be
available at:
http://www.veracast.com/webcasts/bio/investorforum2014/55210199361.cfm
Please visit the website at least 15 minutes prior to the event to
register, download and install any necessary audio or video software to
access the presentation. For those unable to participate in the live
webcast, the replay will be available one hour after the conclusion of
the live event and archived for 90 days following the presentation.
About MetaStat, Inc.
MetaStat, Inc (OTCQB: MTST) is a molecular diagnostic company that
develops and commercializes diagnostic tests for early and reliable
prediction of systemic metastasis, the process by which cancer spreads
from a primary tumor through the bloodstream to other areas of the body.
MetaStat is focused on breast, prostate, lung and colorectal cancers,
where systemic metastasis is responsible for approximately 90% of all
deaths. The Company’s function-based diagnostic platform technology is
based on the identification and understanding of the pivotal role of the
mena protein and its isoforms, a common pathway for the development of
systemic metastatic disease in all epithelial-based solid tumors. Both
the MetaSite Breast™ and MenaCalc™ assays are designed to accurately
stratify patients based on their individual risk of metastasis and to
provide physicians with clinically actionable information to better
"customize" cancer treatment. MetaStat’s testing platform improves
treatment planning decisions by positively identifying patients with a
high-risk of metastasis who need aggressive therapy and by sparing
patients with a low-risk of metastasis from the harmful side effects and
expense of chemotherapy. The company is based in Boston.
Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and such
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. You
are cautioned that such statements are subject to a multitude of risks
and uncertainties that could cause future circumstances, events or
results to differ materially from those projected in the forward-looking
statements as a result of various factors and other risks, including
those set forth in the Company's Form 10-K filed with the Securities and
Exchange Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance
on such statements. The forward-looking statements in this release are
made as of the date hereof and the company undertakes no obligation to
update such statements.
Copyright Business Wire 2014